Trial Profile

A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Isatuximab (Primary) ; Prednisone (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Nov 2024 Results hypothesizing that isatuximab-bendamustine-prednisone would be well-tolerated regimen in TCR MM were published in the Annals of Hematology.
17 Mar 2024 Status changed from active, no longer recruiting to discontinued.
13 Feb 2024 Planned End Date changed from 31 Dec 2023 to 28 Nov 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com